{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', '12.1.9.', 'Emergency Procedures', '89', '12.2.', 'Adverse Event Management', '90', '12.2.1.', 'Rash', '90', '12.2.1.1.', 'Study Drug Administration for Grade 1 or 2 Rashes Considered Related to', 'Study Drug', '90', '12.2.2.', 'Aminotransferase (ALT or AST) Elevation', '90', '12.2.3.', 'Overdose', '91', '12.3.', 'Data Monitoring Committee', '92', '13.', 'STATISTICS', '92', '13.1.', 'Hypotheses', '92', '13.1.1.', 'Primary Hypotheses', '92', '13.1.2.', 'Secondary Hypotheses', '93', '13.1.3.', 'Controlling for Multiplicity', '93', '13.2.', 'Sample Size Considerations', '94', '13.2.1.', 'Sample Size for Study BCX7353-301 Alone', '95', '13.2.2.', 'Sample Size for the Combined Analysis of Studies BCX7353-301 and', 'BCX7353-302', '95', '13.3.', 'Stratification', '95', '13.4.', 'Statistical Methods', '95', '13.4.1.', 'Analysis Populations', '96', '13.4.1.1.', 'Screen Failures', '96', '13.4.1.2.', 'Intent-to-Treat Population', '96', '13.4.1.3.', 'Safety Population', '96', '13.4.1.4.', 'Per Protocol Population', '96', '13.4.1.5.', 'Completers Population', '96', '13.4.1.6.', 'Pharmacodynamic Population', '96', '13.4.1.7.', 'PK Concentration/PD Population', '96', '13.4.2.', 'General Considerations for Data Analysis', '97', '13.4.3.', 'Subject Demographic and Disposition Data', '97', '13.4.4.', 'Analysis of Efficacy Variables', '97', '13.4.4.1.', 'Primary Efficacy Analysis', '98', '13.4.4.2.', 'Secondary and Exploratory Efficacy Analyses', '98', '13.4.5.', 'Planned Analyses', '99', '21']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', '13.4.6.', 'Analysis of Safety Variables', '99', '13.4.7.', 'Health Outcome Analyses', '100', '13.4.8.', 'Pharmacokinetic Analyses', '101', '13.4.9.', 'Pharmacodynamic Analyses', '101', '13.4.10.', 'PK Concentration /Pharmacodynamic Analyses', '101', '14.', 'STUDY ADMINISTRATION', '101', '14.1.', 'Regulatory and Ethical Considerations', '101', '14.1.1.', 'Regulatory Authority Approvals', '101', '14.1.2.', 'Institutional Review Board and Ethics Committee Approvals', '102', '14.1.3.', 'Subject Informed Consent: Adults', '102', '14.1.4.', 'Subject Informed Consent: Adolescents', '103', '14.1.5.', 'Investigator Reporting Requirements', '103', '14.2.', 'Study Monitoring', '103', '14.3.', 'Quality Assurance', '104', '14.4.', 'Study Termination and Site Closure', '104', '14.5.', 'Records Retention', '105', '14.6.', 'Confidentiality of Information and Data', '105', '14.7.', 'Study Publication', '105', '15.', 'REFERENCES', '106', '16.', 'APPENDICES', '108', '16.1.', 'DMID Adult Adverse Event Table (DRAFT, Publish Date: November 2007)', '108', 'LIST OF TABLES', 'Table 1:', 'Abbreviations and Specialist Terms', '24', 'Table 2:', 'Schedule of Assessments: Part 1 of Study BCX7353-301', '55', 'Table 3:', 'Schedule of Assessments: Part 2 of Study BCX7353-301', '59', 'Table 4:', 'Schedule of Assessments: Part 3 of Study BCX7353-301', '61', 'Table 5:', 'Clinical Laboratory Evaluations', '75', 'Table 6:', 'Power Calculations to Support Sample Size', '95', '22']\n\n###\n\n", "completion": "END"}